Osteoporosis: Underrated, underdiagnosed and undertreated

Medical Journal of Australia

Volumn 180, Issue 5 SUPPL., 2004, Pages

  Nguyen, Tuan V ^a   Center, Jacqueline R ^a   Eisman, John A ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; DIURETIC AGENT; ESTROGEN; GLUCOCORTICOID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THYROXINE; VITAMIN D;

ARTICLE; AUSTRALIA; BONE DENSITY; CAUSE OF DEATH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ELDERLY CARE; ESTROGEN THERAPY; FRAGILITY FRACTURE; GENETIC RISK; HEALTH CARE COST; HEREDITY; HIP FRACTURE; HUMAN; INSTITUTIONAL CARE; LIFESTYLE; MORBIDITY; OSTEOPOROSIS; PREDICTION; PROTECTIVE EQUIPMENT; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 1542300124     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb05908.x     Document Type: Article

References (61)

1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936.
2. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
3. Randell A, Sambrook PN, Nguyen TV, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 1995; 6: 427-437.
4. The burden of brittle bones - costing osteoporosis in Australia. Presented for Osteoporosis Australia by Access Economics Pty Ltd. Canberra: Access Economics, September 2001.
5. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-882.
6. Hasserius R, Karlsson MK, Nilsson BE, et al. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003; 14: 61-68.
7. Randell AR, Nguyen TV, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 2000; 11: 460-466.
8. Scaf-Klomp W, van Sonderen E, Sanderman R, et al. Recovery of physical function after limb injuries in independent older people living at home. Age Ageing 2001; 30: 213-219.
9. Nguyen TV, Sambrook PN, Kelly PJ, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993; 307: 1111-1115.
10. Melton LJ, Atkinson EJ, O'Fallon WM, et al. Longterm fracture risk prediction by bone mineral density assessed at different skeletal sites. J Bone Miner Res 1993; 8: 1227-1233.
11. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-1259.
12. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368-381.
13. Nguyen TV, Eisman JA. Risk factors for low bone mass in elderly men. In: Orwoll ES, editor. Osteoporosis in men. San Diego: Academic Press, 1999: 335-362.
14. Schott AM, Weill-Engerer S, Hans D, et al. Ulstrasound discriminates patients with hip fracture equally well as dual energy x-ray absorptiometry and independent of bone mineral density. J Bone Miner Res 1995; 10: 243-249.
15. Glüer CC, Cummings SR, Bauer DC, et al. Osteoporosis: association of recent fractures with quantitative ultrasound findings. Radiology 1996; 199: 725-732.
16. Bauer DC, Gluer CC, Cauley JA, et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997; 157: 629-634.
17. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996; 348: 511-514.
18. Nguyen TV, Howard GM, Kelly PJ, Eisman JA. Bone mass, lean mass and fat mass: same genes or same environments. Am J Epidemiol 1998; 147: 3-16.
19. Howard GM, Nguyen TV, Harris M, et al. Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: a twin study. J Bone Miner Res 1998; 13: 1318-1327.
20. Flicker L, Hopper JL, Rodgers L, et al. Bone density determinants in elderly women: a twin study. J Bone Miner Res 1995; 10: 1607-1613.
21. Deng HW, Chen WM, Recker S, et al. Genetic determination of Colles' fracture and differential bone mass in women with and without Colles' fracture. J Bone Miner Res 2000; 15: 1243-1252.
22. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-773.
23. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-1686.
24. Khosla S, Bilezikian JP. The role of estrogens in men and androgens in women. Endocrinol Metab Clin North Am 2003; 32: 195-218.
25. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841-1850.
26. Nguyen TV, Jones G, Sambrook PN, et al. The effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures. J Clin Endocrinol Metab 1994; 9: 2709-2714.
27. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739.
28. Nguyen TV, Sambrook PN, Eisman JA. Bone loss, physical activity, and weight change in elderly women: The Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 1998; 13: 1458-1467.
29. Takeda S, Elefteriou F, Karsenty G. Common endocrine control of body weight, reproduction, and bone mass. Ann Rev Nutr 2003; 23: 403-411.
30. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity and body mass index. J Bone Miner Res 2000; 15: 322-331.
31. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68: 259-270.
32. Nguyen TV, Kelly PJ, Sambrook PN, et al. Lifestyle factors and bone density in the elderly: implications for osteoporosis prevention. J Bone Miner Res 1994; 9: 1339-1346.
33. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997; 315: 841-846.
34. Hermann AP, Brot C, Gram J, et al. Premenopausal smoking and bone density in 2015 perimenopausal women. J Bone Miner Res 2000; 15: 780-787.
35. Adinoff AD, Hollister MD. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-268.
36. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999; 2: 323-342.
37. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-2026.
38. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122: 17-23.
39. Torgerson DJ, Bell-Syer SEM. A meta-analysis of hormone replacement therapy for fracture prevention. JAMA 2001; 286: 2096-2097.
40. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333.
41. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women - three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch intern Med 2000; 160: 3444-3450.
42. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 2197-2202.
43. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282: 637-645.
44. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial. Lancet 1996; 348: 1535-1541.
45. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA 1997; 227: 1159-1164.
46. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-4124.
47. Reginster J, Minne HW, Sorensen OH, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
48. Harris ST, Watts NB, Genant HK, et al, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999; 282: 1344-1352.
49. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
50. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999; 130: 897-904.
51. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomised, controlled clinical trial. J Clin Endocrinol Metab 1999; 84: 3076-3081.
52. 3 and calcium to prevent hip fracture in elderly women. N Engl J Med 1992; 327: 1637-1642.
53. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.
54. Gillespie WJ, Avenell A, Henry DA, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
55. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database of Systematic Reviews. Cochrane Library 2001, Issue 4. Available at: www.update-software.com/abstracts/ab001255.htm (accessed Dec 2003).
56. van Schoor NM, Smit JH, Twisk JW, et al. Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA 2003; 289: 1957-1962.
57. Gehlbach SH, Fournier M, Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health 2002; 92: 271-273.
58. Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000; 82-A: 1063-1070.
59. Harrington JT, Broy SB, Derosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002; 47: 651-654.
60. Bauer DC. Osteoporotic fractures: ignorance is bliss? Am J Med 2000; 109: 338-339.
61. Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000 Sep; 109: 326-328.